Of reservoirs, persistence and delays.

While most here are concerned with a green portfolio and moonshots, Biotron are trying to find out the hows and whys of BIT225’s action. Most will remember how long it took last time to get certain phrases out of experts. It’s not just about a cure. I don’t think these delays are a sign of problems. Apart from the ‘coming weeks’ marketing ploy used to pump the stock, of course.

This might help you understand why the trial results are linked….. proving the mode of action, and then how that might fit in with long term dosing with or without other compounds.

https://www.npr.org/sections/health...,spearheading research into viral persistence.